Lymphoplasmacytic Lymphoma Clinical Trial
Official title:
Phase II Study of Campath-1H in Patients With Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia)
The purpose of this study is to determine the safety and effects (good or bad) of Campath-1H antibody in the treatment of lymphoplasmacytic lymphoma.
- Patients will receive 3 test doses of Campath-1H (3mg, 10mg, 30mg). If the patient
tolerates these three test doses, then they will receive a total of 6 weeks of
Campath-1H therapy three times a week.
- After the patient receives the first 6 weeks of therapy at the 30mg therapeutic dose
they will be re-assessed by blood testing. If it is determined that their disease has
progressed in the period of time while the patient was on Campath-1H, the patient will
be removed from the study.
- If it is determined that the patient has achieved a complete remission after 6 weeks of
Campath-1H treatment a bone marrow biopsy will be performed to confirm complete
remission and the patient will not receive any additional treatment but will be
followed for a period of 2 years.
- If the disease has remained stable or partial response has been achieved the patient
will enter the second phase of therapy in which they will receive an additional 6 weeks
of Campath-1H therapy. The patient will then be reassessed as described above.
- No additional therapy (as part of this study) will be performed after a 12 week course
of Campath-1H.
- While the patient is on Campath-1H blood test will be performed at 3-6 month intervals
over a period extending for 2 years following the last treatment. Bone marrow biopsies
and/or aspirations will be conducted as necessary.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04883437 -
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
|
Phase 2 | |
| Recruiting |
NCT04545762 -
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
|
Phase 1 | |
| Active, not recruiting |
NCT03133221 -
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
|
Phase 2 | |
| Completed |
NCT03019666 -
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
|
Phase 1 | |
| Recruiting |
NCT03335098 -
Study of VTD in Waldenstrom's Macroglobulinemia
|
Phase 2 | |
| Active, not recruiting |
NCT00719888 -
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
|
Phase 2 | |
| Recruiting |
NCT00923507 -
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
|
||
| Completed |
NCT01314014 -
Imexon for Relapsed Follicular and Aggressive Lymphomas
|
Phase 2 | |
| Completed |
NCT00142116 -
Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia
|
Phase 2 | |
| Recruiting |
NCT04799275 -
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT02339922 -
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
|
Phase 2 | |
| Terminated |
NCT03601819 -
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
|
Phase 1 | |
| Active, not recruiting |
NCT02722668 -
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
|
Phase 2 | |
| Completed |
NCT02661035 -
Allo HSCT Using RIC for Hematological Diseases
|
Phase 2 | |
| Recruiting |
NCT03314974 -
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
|
Phase 2 | |
| Recruiting |
NCT06340737 -
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
|
Phase 1 | |
| Completed |
NCT01282424 -
Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas
|
Phase 2 | |
| Completed |
NCT04858568 -
Immune Responses to COVID-19 Vaccination in Lymphoma Patients
|
||
| Completed |
NCT00644189 -
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
| Completed |
NCT00566332 -
Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia
|
Phase 3 |